 | Up a level |
Ataseven, B., Rhiem, K., Staniczok, C., Heitz, F., Pauly, N., Moubarak, M., Concin, N., Traut, A., Schmutzler, R. and Harter, P. (2022). Prevalence and oncological outcome of patients with primary epithelial ovarian cancer (EOC) carrying gene mutations or variants of unknown signifikance (VUS) detected by germline gene panel testing. Geburtshilfe Frauenheilkd., 82 (10). S. E44 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Ataseven, B., Tripon, D., Schwameis, R., Harter, P., Rhiem, K., Schneider, S., Heikaus, S., Baert, T., Alesina, P., Heitz, F., Traut, A., Groeben, H. T., Schmutzler, R. and du Bois, A. (2021). Impact of BRCA1/2 Germline Status on intraperitoneal Tumor Distribution, Operability, and Incidence of postoperative Complications in Patients with epithelial Ovarian Cancer. Geburtshilfe Frauenheilkd., 81 (4). S. E2 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Berling-Ernst, A., Yahiaoui-Doktor, M., Kiechle, M., Engel, C., Lammert, J., Grill, S., Dukatz, R., Rhiem, K., Baumann, F. T., Bischoff, S. C., Erickson, N., Schmidt, T., Niederberger, U., Siniatchkin, M. and Halle, M. (2022). Predictors of cardiopulmonary fitness in cancer-affected and -unaffected women with a pathogenic germline variant in the genes BRCA1/2 (LIBRE-1). Sci Rep, 12 (1). BERLIN: NATURE PORTFOLIO. ISSN 2045-2322
Fasching, P. A., Link, T., Hauke, J., Seither, F., Jackisch, C., Klare, P., Schmatloch, S., Hanusch, C., Huober, J., Stefek, A., Seiler, S., Schmitt, W. D., Uleer, C., Doering, G., Rhiem, K., Schneeweiss, A., Engels, K., Denkert, C., Schmutzler, R. K., Hahnen, E., Untch, M., Burchardi, N., Blohmer, J-U and Loibl, S. (2021). Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study). Ann. Oncol., 32 (1). S. 49 - 58. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Holly, J., Harter, P., Ataseven, B., Moubarak, M., Schwameis, R., Heikaus, S., Concin, N., Rhiem, K., Denkert, C. and Heitz, F. (2022). HRD Testing and BRCA1/2 Germline Testing in routine clinical Practice in Female Patients with primary Ovarian Cancer. Geburtshilfe Frauenheilkd., 82 (4). S. E5 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Imterat, M., du Bois, A., Harter, P., Rhiem, K., Heitz, F., Concin, N., Traut, A., Schmutzler, R. and Ataseven, B. (2022). Incidence and prognostic impact of pathogenic germline mutations in gene panel testing of primary advanced epithelial ovarian cancer patients. Geburtshilfe Frauenheilkd., 82 (10). S. E97 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804
Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J. U., Furlanetto, J., Zahm, D. M., Hanusch, C., Thomalla, J., Jackisch, C., Staib, P., Link, T., Rhiem, K., Solbach, C., Fasching, P. A., Nekljudova, V., Denkert, C. and Untch, M. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann. Oncol., 33 (11). S. 1149 - 1159. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J. -U., Grischke, E. -M., Furlanetto, J., Tesch, H., Hanusch, C., Engels, K., Rezai, M., Jackisch, C., Schmitt, W. D., von Minckwitz, G., Thomalla, J., Kuemmel, S., Rautenberg, B., Fasching, P. A., Weber, K., Rhiem, K., Denkert, C. and Schneeweiss, A. (2022). A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study (vol 30, pg 1279, 2019). Ann. Oncol., 33 (7). S. 743 - 745. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Reinisch, M., Blohmer, J-U., Link, T., Just, M., Untch, M., Stoetzer, O., Fasching, P. A., Schneeweiss, A., Wimberger, P., Seiler, S., Huober, J., Thill, M., Jackisch, C., Rhiem, K., Solbach, C., Hanusch, C., Denkert, C., Engels, K., Nekljudova, V. and Loibl, S. (2022). Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC). Ann. Oncol., 33. S. S166 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Staniczok, C., Ataseven, B., Heitz, F., Harter, P., Rhiem, K., Pauly, N., Traut, A. and Moubarak, M. (2022). Prevalence and clinical characterization of concurrent multiple deleterious germline mutations in German patients with epithelial ovarian cancer. Geburtshilfe Frauenheilkd., 82 (10). S. E165 - 2. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8804